26
|
Moermans C, Bonnet C, Willems E, Baron F, Nguyen M, Henket M, Sele J, Corhay JL, Beguin Y, Louis R. Sputum cytokine levels in patients undergoing hematopoietic SCT and comparison with healthy subjects and COPD: a pilot study. Bone Marrow Transplant 2014; 49:1382-8. [DOI: 10.1038/bmt.2014.164] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2014] [Revised: 06/08/2014] [Accepted: 06/12/2014] [Indexed: 01/08/2023]
|
27
|
Detry O, Jouret F, Vandermeulen M, Erpicum P, Delens L, Grégoire C, Briquet A, Weekers L, Baudoux E, Lechanteur C, Beguin Y. [Mesenchymal stromal cells and organ transplantation]. REVUE MEDICALE DE LIEGE 2014; 69 Spec No:53-56. [PMID: 25796799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Mesenchymal stromal cells (MSC) are multipotent and self-renewing cells. MSC are studied for their in vivo and in vitro immunomodulatory effects, in the prevention or the treatment of isehemic injury, and for their potential properties of tissue or organ reconstruction. Over the last few years, the potential role of MSC in organ transplantation has been studied both in vitro and in vivo, and their properties make them an ideal potential cell therapy after solid organ transplantation. A prospective, controlled, phase 1-2 study has been initiated at the CHU of Liege, Belgium. This study assesses the potential risks and benefits of MSC infusion after liver or kidney transplantation. Even if the preliminary results of this study look promising, solely a prospective, randomized, large scale, phase 3 study will allow the clinical confirmation of the theoretical benefits of MSC in solid organ transplantation.
Collapse
|
28
|
Caers J, Binsfeld M, Muller J, Heusschen R, Beguin Y. [Monoclonal gammopathies of undetermined significance - update for referring physicians]. REVUE MEDICALE DE LIEGE 2014; 69 Spec No:41-46. [PMID: 25796797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Monoclonal gammopathies of undetermined significance (MGUS) are frequently diagnosed in the global population. Because of its possible transformation into a hematological malignancy, the identification of a MGUS requires a regular and generally long follow-up. However, this risk of transformation differs between the individuals and different laboratory criteria have been identified as predictive factors for progression and were combined in scoring systems that allow correct classification of individuals. The management of these patients needs to be adapted according to the calculated risk profile.
Collapse
|
29
|
Moermans C, Poulet C, Henket M, Bonnet C, Willems E, Baron F, Beguin Y, Louis R. Lung function and airway inflammation monitoring after hematopoietic stem cell transplantation. Respir Med 2013; 107:2071-80. [DOI: 10.1016/j.rmed.2013.10.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/24/2013] [Revised: 09/20/2013] [Accepted: 10/08/2013] [Indexed: 10/26/2022]
|
30
|
Hafraoui K, De Prijck B, Beguin Y. [Chronic myelomonocytic leukemia: from diagnosis to treatment]. REVUE MEDICALE SUISSE 2013; 9:1512-1517. [PMID: 24024420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Chronic myelomonocytic leukemia (CMML) is a disease typically of the elderly. It is suspected when monocytosis reaches 1000/microl. It may be associated with "B" symptoms (fever, sweating, and weight loss) but also visceral, skin and autoimmune complications. Current treatment strategies aim at reducing the symptoms and have no curative goals. In this context hypomethylating agents have shown a good efficacy. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative option but remains difficult to perform in elderly patients population, even if transplantation with a reduced intensity conditioning has reduced the risks. A new prognostic scoring helps to recognize the patients with poor prognosis and to better selected candidates for the HSCT.
Collapse
|
31
|
Collins P, Vijgen S, De Prijck B, Blétard N, Beguin Y, Delvenne P. [Clinical case of the month. Chemotherapy, immunodepression and secondary neoplasms: a case report]. REVUE MEDICALE DE LIEGE 2013; 68:418-422. [PMID: 24053102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
We report the case of a multi-metastatic mucinous adenocarcinoma of the colon discovered pre-mortem in a patient with a history of multiple myeloma. This case gives the opportunity to discuss the prognostic value of histological typing of colorectal cancer and secondary neoplasms to chemotherapy and/or immunodepression.
Collapse
|
32
|
Guièze R, Damaj G, Robin M, Mohty M, Michallet M, Tabrizi R, Beguin Y, Blaise D, Roosweil D, Bulabois C, Legrand F, Huynh A, Cornillon J, Contentin N, Suarez F, Lioure B, Maillard N, Clément L, Guillerm G, Rubio M, Garnier F, Yakoub-Agha I. P-212 Therapeutic management of MDS patients relapsing after allo-SCT: A large-scale study on behalf of the SFGM-TC. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70259-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
33
|
Damaj G, Duhame A, Robin M, Milpied N, Michallet M, Chevallier P, Beguin Y, Nguyen S, Lioure B, Blaise D, Maillard N, Rubio M, Fegueux N, Cornillon J, Francois S, Mohty M, Huyn A, Bulabois C, Fenaux P, Yakoub-Agha I. O-014 Azacitidine versus best supportive care before non-myeloablative allogeneic stem cell transplantation for MDS: A study by the SFGM-TC. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70036-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
34
|
Servais S, Willems E, Beguin Y, Baron F. [Allogeneic hematopoietic stem cell transplantation: what is the upper age limit?]. REVUE MEDICALE DE LIEGE 2013; 68:38-43. [PMID: 23444827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
In the last decades, the upper age limit for allogeneic hematopoietic cell transplantation has increased from 50-60 years to 70-75 years of age, in part due to the development of allogeneic transplantation following reduced-intensity or truly nonmyeloablative conditioning. This review describes challenges and opportunities of allogeneic hematopoietic cell transplantation in the elderly.
Collapse
|
35
|
Frusch N, Servais S, De Prijck B, Corhay JL, Beguin Y, Louis R, Duysinx B. Spontaneous pneumomediastinum caused by bleomycin-induced pneumonitis. Acta Clin Belg 2012. [PMID: 23189547 DOI: 10.2143/acb.67.5.2062693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
We report the case of a 24-yr-old woman treated for lymphoma who developed bleomycin-induced interstitial pneumonia. This interstitial pneumonia was complicated by spontaneous pneumomediastinum. Pneumomediastinum is an unfrequent side effect of high dose bleomycin-induced pneumonitis (BIP) and we describe the first case occurring with low-dose of bleomycin.
Collapse
|
36
|
Bonnet C, De Prijck B, Lejeune M, Fassotte MF, Van Den Neste E, Beguin Y. [Diffuse large B cell lymphoma: management in 2012]. REVUE MEDICALE SUISSE 2012; 8:1582-1590. [PMID: 22988711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Diffuse Large B Cells Lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and comprises a large number of different entities with different clinico-pathological characteristics. The role of positron emission tomography is essential during the initial staging and post treatment assessment, and potentially at early- or mid-treatment evaluation of response. First line therapy comprises immuno-chemotherapy with rituximab and different cytotoxic agents that differ for components, dosages and frequency of administration taking worldwide-recognized pre-treatment prognostic variables into account. After relapse, peripheral blood stem cells transplantation remains the only chance of cure. This review attempts to summarize the current state of our knowledge by highlighting the leads pursued to further improve current therapeutic results.
Collapse
|
37
|
Aapro M, Österborg A, Gascón P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 2012; 23:1954-1962. [PMID: 22575608 DOI: 10.1093/annonc/mds112] [Citation(s) in RCA: 118] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Chronic diseases reduce the availability of iron for effective erythropoiesis. This review summarises clinical consequences of iron deficiency (ID) and anaemia in cancer patients, mechanisms how impaired iron homeostasis affects diagnosis and treatment of ID, and data from clinical trials evaluating i.v. iron with or without concomitant erythropoiesis-stimulating agents (ESAs). DESIGN Clinical trial reports were identified in PubMed and abstracts at relevant major congresses. RESULTS Reported prevalence of ID in cancer patients ranges from 32 to 60% and most iron-deficient patients are also anaemic. Randomised clinical trials have shown superior efficacy of i.v. iron over oral or no iron in reducing blood transfusions, increasing haemoglobin, and improving quality of life in ESA-treated anaemic cancer patients. Furthermore, i.v. iron without additional ESA should be evaluated as potential treatment in patients with chemotherapy-induced anaemia. At recommended doses, i.v. iron is well tolerated, particularly compared with oral iron. No serious drug-related adverse effects were seen during long-term use in renal disease and no effect on tumour growth has been observed in trials with anaemic cancer patients. CONCLUSIONS Reliable diagnosis and treatment of ID are recommended key steps in modern cancer patient management to minimise impact on quality of life and performance status.
Collapse
|
38
|
Vertenoeil G, Servais S, Beguin Y. [How to explore a fever of unknown origin in adult patients?]. REVUE MEDICALE DE LIEGE 2012; 67:391-397. [PMID: 22984757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Fever of unknown origin (FUO), with more than 200 potential causes, can represent a real diagnostic challenge. For the work-up of FUO, the first step is to pay attention to each element revealed by a detailed history, a complete physical examination and by some basic diagnostic tests. These elements may constitute some clues that can guide the physician for the prescription of further appropriate diagnostic examinations and procedures. If there is no real specific clues,a pet-scan seems to be useful for the work-up of FUO.
Collapse
|
39
|
De Bock M, Fillet M, Merville MP, Gothot A, Beguin Y, Baron F. Kinetics of IL-7 and IL-15 Levels After Allogeneic Peripheral Blood Stem Cell Transplantation (allo-PBSCT) Following High-Dose or Nonmyeloablative Conditioning. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
40
|
Caers J, Bonnet C, Graux C, De Prijck B, Beguin Y. [Current management of myelodysplastic syndromes]. REVUE MEDICALE SUISSE 2011; 7:1634-1643. [PMID: 21972730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Treatment of myelodysplastic syndromes (MDS) has improved in recent years with better results of allogeneic stem cell therapy (SCT), the advent of new therapeutic options such as hypomethylating agents and lenalidomide, the introduction of iron chelation therapy and the implication of erythropoietic stimulating agents in the treatment of anemia. In this review, we summarize the different diagnostic and prognostic criteria and outline the different treatment options we have in 2011.
Collapse
|
41
|
Bonnet C, Caers J, De Prijck B, Hafraoui K, Beguin Y. [Mantle cell lymphoma: management in 2011]. REVUE MEDICALE SUISSE 2011; 7:1644-1649. [PMID: 21972731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Mantle cell lymphoma is a rare form of non Hodgkin lymphomas. Diagnosis is made by demonstrating a typical immunophenotype as well as the presence of a translocation between chromosomes 11 and 14 with overexpression of cyclin D1. First line therapy for young patients consists in 3 cycles of "R-CHOP21" alternated with 3 "R-DHAP21" and followed by an autograft conditioned by total body irradiation, cyclophosphamide and aracytine. For patients over 65 years of age, the treatment of choice consists in 8 cycles of "R-CHOP21". Maintenance treatment is under evaluation. Allografting is the only chance of cure in relapsed patients with good performance status. Targeted therapies will improve the prognosis of this disease.
Collapse
|
42
|
Aapro MS, Beguin Y, Bokemeyer C, Glaspy JA, Hedenus M, Littlewood TJ, Ludwig H, Osterborg A, Rzychon B, Mitchell D. Diagnosis, treatment, and use of intravenous iron for chemotherapy-induced anemia in Europe. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e19557] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
43
|
Bruck F, Baron F, Dubois S, Briquet A, Hanon-Absil M, Belle L, Menten C, Beguin Y, Humblet-Baron S. Rapamycin Delays Xenogeneic Acute Graft Versus Host Disease (aGVHD) in Nod/Scid/Il2RγNull (NSG) Mice: Impact of Regulatory T Cells. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.535] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
44
|
Roufosse R, Beguin Y. [Therapeutic observance in haematology: the particular case of chronic myeloid leukemia]. REVUE MEDICALE DE LIEGE 2010; 65:409-412. [PMID: 20684429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Therapeutic adhesion is essential because it modulates the efficiency of treatment, the occurrence of side effects and the socioeconomic costs possibly associated with it. In haematology, in the particular case of Chronic Myeloid Leukemia, the "ADAGIO" study performed by Noens and co-workers demonstrated that therapeutic observance is lower than the practitioners, the patients and the family members believe it is. This lack of adhesion can engender a decrease of the efficiency of treatment, in particular by imatinib. Factors such as the chronicity of the disease and the length of treatment modify therapeutic adhesion over time. Simple methods, addressing both the patient and the doctor should be developed to improve this therapeutic adhesion.
Collapse
|
45
|
Jaspers A, Baron F, Bonnet C, De Prijck B, Fassotte MF, Beguin Y. [Mantle cell lymphoma]. REVUE MEDICALE DE LIEGE 2010; 65:171-176. [PMID: 20499817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Mantle cell lymphoma comprises 3 to 10% of non-Hodgkin's lymphomas. Cyclin D1 expression due to t(11 ;14) (q13 ;32) is considered as a hallmark of this lymphoma and plays a pivotal role in the pathophysiology of lymphoma transformation. Median age at diagnosis ranges from 60 to 70 years, and diagnosis is often made at an advanced stage with widespread lymphadenopathy and extranodular (particularly bone marrow and gastrointestinal) infiltration. First line treatment consists of combination chemotherapy followed with autologous hematopoietic cell transplantation (HCT) in younger patients, while allogeneic HCT following non-myeloablative conditioning might have a role in patients relapsing after autologous HCT.
Collapse
|
46
|
Humblet-Baron S, Willems E, Dengis O, Seidel L, Beguin Y, Baron F. Prediction Of Acute GVHD Following Nonmyeloablative Conditioning By Measurement Of Tumor Necrosis Factor-Receptor 1 (TNFR1) At Baseline And At Day 7 After Transplantation. Biol Blood Marrow Transplant 2010. [DOI: 10.1016/j.bbmt.2009.12.442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
47
|
Servais S, Willems E, Beguin Y, Baron F. [Chronic graft-versus-host disease: a multidisciplinary approach]. REVUE MEDICALE DE LIEGE 2010; 65:81-87. [PMID: 20344918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Chronic Graft-Versus-Host Disease (GVHD) is a frequent complication of allogeneic hematopoietic cell transplantation. This review article describes recent advances in the classification and treatment of chronic GVHD.
Collapse
|
48
|
Hafraoui K, Beguin Y, Baron F. [Secondary malignancies after allogeneic hematopoietic cell transplantation]. REVUE MEDICALE DE LIEGE 2009; 64:496-499. [PMID: 19911662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
This article reviews the incidence, risk factors and prevention of secondary malignancies after allogeneic hematopoietic cell transplantation.
Collapse
|
49
|
Willems E, Baron F, Seidel L, Frère P, Fillet G, Beguin Y. Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning. Bone Marrow Transplant 2009; 45:689-93. [DOI: 10.1038/bmt.2009.230] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
50
|
Bonnet C, Beguin Y, Deprijck B, de Leval L, Fillet G. [Current treatment of follicular lymphoma]. REVUE MEDICALE SUISSE 2009; 5:1663-1667. [PMID: 19772198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
After diffuse large B-cell lymphoma, follicular lymphoma is the most frequent non-Hodgkin's lymphoma. It remains incurable, except for localized diseases. Advanced disease has to be treated only in the presence of clinical and/or biology aggressiveness. These patients should be treated by rituximab (Mab-Thera) associated to polychemotherapy comprising cyclophosphamide, vincristine and prednisone. After this therapy, the benefit of rituximab in maintenance has to be confirmed. Autologous stem cell transplantation is now reserved for young patients in first relapse. Allogenic stem cell transplantation is also an interesting option. The other therapeutic options comprise radio-immunotherapy with 90Y ibritumomab tiuxetan (Zevalin) and bortezomib (Velcade).
Collapse
MESH Headings
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Boronic Acids/administration & dosage
- Bortezomib
- Chemotherapy, Adjuvant
- Cyclophosphamide/administration & dosage
- Hematopoietic Stem Cell Transplantation
- Humans
- Lymphoma, Follicular/drug therapy
- Lymphoma, Follicular/radiotherapy
- Lymphoma, Follicular/therapy
- Prednisone/administration & dosage
- Prognosis
- Pyrazines/administration & dosage
- Radioimmunotherapy
- Radiotherapy, Adjuvant
- Risk Factors
- Rituximab
- Transplantation, Autologous
- Transplantation, Homologous
- Treatment Outcome
- Vincristine/administration & dosage
Collapse
|